Recombinant human NTRK2 /TRKB Protein, His Tag, 100µg

Background
Neurotrophic tyrosine kinase receptor type 2 (NTRK2) also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is “ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate”. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

Source
Recombinant Human NTRK2 /TRKB Protein (rhNTRK2), His Tag (NT2-H5228) is expressed from human 293 cells (HEK293). It contains AA Cys 32 - His 430 (Accession # AAH31835).
Predicted N-terminus: Cys 32

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 45.2 kDa. The protein migrates as 60-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% purity as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Investigating 7,8-Dihydroxyflavone to combat maternal immune activation effects on offspring gene expression and behaviour"
Gillespie, Dunn, Sundram et al
Prog Neuropsychopharmacol Biol Psychiatry (2024)
(2) "Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers"
Willis, Au, Hejazi et al
J Manag Care Spec Pharm (2024) 30 (7), 672-683
(3) "Fluoxetine and ketamine trigger the p75NTR proteolytic pathway and enhance extinction memory and brain plasticity through p75NTR"
Diniz, Crestani, Casarotto et al
Biol Psychiatry (2024)
Showing 1-3 of 7115 papers.